

16 March 2026

## Treatment of Cancers (to include ovarian, fallopian tube, primary peritoneal and prostate cancers)

I would be grateful if you could answer the questions below in relation to the number of patients treated with specific medicines. Please include data for all hospitals in the Health and Social Care Trust.

**Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between 1<sup>st</sup> October 2025 and the end of December 2025, or latest 3-months for which data are available?**

Name of medicine	Number patients treated
1.1 Niraparib (Zejula)	54
1.2 Rucaparib (Rubraca)	<5
1.3 Olaparib (Lynparza)	25

**Use of <5 (less than five):** We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party, as the small numbers involved could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

**Q2. How many patients were treated for ovarian, fallopian tube or primary peritoneal cancers, with the following medicines as monotherapy or in combination, in the 3 months between 1<sup>st</sup> October 2025 to the end of December 2025, or latest 3-months for which data are available?**

Name of medicine	Number patients treated
2.1 Olaparib in total	23
2.2 Olaparib monotherapy	23
2.3 Olaparib + bevacizumab in combination	0
2.4 Bevacizumab total	19
2.5 Bevacizumab monotherapy	0
2.6 Bevacizumab + carboplatin + paclitaxel, or bevacizumab + gemcitabine + carboplatin, or bevacizumab + paclitaxel + pegylated liposomal doxorubicin	19

16 March 2026

**Q3. How many patients were treated for the following indications by product, in the 3 months between 1<sup>st</sup> October 2025 and 31<sup>st</sup> December 2025, or latest 3-months for which data are available?**

Name of medicine	Line of Therapy (indication) and NICE TA code	Number patients treated
3.3 Rucaparib (Rubraca)	1L advanced ovarian cancer in response to 1L platinum chemotherapy (TA1055)	All ovarian cancer <5
3.4 Rucaparib (Rubraca)	Relapsed platinum-sensitive ovarian cancer (TA1007)	As above

**Q4. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between 1<sup>st</sup> October 2025 to the end of December 2025, or latest 3-months for which data are available?**

Name of medicine	Number patients treated
4.1 Abiraterone (Zytiga or generic abiraterone)	50
4.2 Apalutamide (Erleada)	22
4.3 Cabazitaxel (Jevtana or generic cabazitaxel)	6
4.4 Darolutamide (Nubeqa)	27
4.5 Enzalutamide (Xtandi)	161
4.6 Talazoparib (Talzenna)	<5
4.7 Docetaxel	75
4.8 Relugolix (Orgovyx, Ryeqo)	0
4.9 Olaparib (Lynparza)	25

**Q5. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between 1<sup>st</sup> October 2025 to the end of December 2025, or latest 3-months for which data are available?**

Name of medicine	Number patients treated
5.1 Docetaxel for prostate cancer	13
5.2 Olaparib (Lynparza) for prostate cancer	<5
5.3 Talazoparib (Talzenna) for prostate cancer	0
5.4 Relugolix (Orgovyx) for prostate cancer	0

16 March 2026

**Q6. How many patients received their first cycle or first dose of the following products in the 3 months between 1<sup>st</sup> October 2025 to the end of December 2025, or latest 3-months for which data are available?**

Name of medicine	Number patients treated in Cycle 1 or Dose 1
6.1 Abiraterone (Zytiga or generic abiraterone)	6
6.2 Apalutamide (Erleada)	<5
6.3 Cabazitaxel (Jevtana or generic cabazitaxel)	<5
6.4 Darolutamide (Nubeqa)	17
6.5 Enzalutamide (Xtandi)	11

**Q7. How many patients were treated with the following combinations in the 3 months between 1<sup>st</sup> October 2025 to the end of December 2025, or latest 3 months for which data are available? Please give total number of patients and number of patients receiving their first dose or first cycle.**

Name of medicine	<u>Total</u> Number patients treated	Number patients received <u>cycle 1</u> or <u>dose 1</u>
7.1 Darolutamide (Nubeqa) + Docetaxel	<5	<5
7.2 Darolutamide (Nubeqa) monotherapy	16	16
7.3 Olaparib (Lynparza) + Abiraterone	0	0

**Q8. How many patients received the following products for non-metastatic hormone sensitive prostate cancer in the 3 months between 1<sup>st</sup> October 2025 to the end of December 2025, or latest 3-months for which data are available?**

Name of medicine	Number patients treated
8.1 Abiraterone	50
8.2 Enzalutamide	161